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Crohn's disease is a chronic inflammatory disorder of the 
gut and is classified as one type of inflammatory bowel 
disease. More than 400 000 people are affected by Crohn‟s 
disease in North America 1. Epidemiological studies 
suggest that this disease occurs in genetically susceptible 
individuals as a result of defects in mucosal barrier 
function and dysregulated Th1-type mucosal inflammation 
2, 3. In Crohn‟s disease, inflammation can affect any part of 
the gastrointestinal tract, from the mouth to the anus. Most 
common symptoms include abdominal pain, diarrhea, 
vomiting, and weight loss 3. There is no cure for Crohn‟s 
disease and surgery cannot be used to treat this disease 4. 
Medications used to treat Crohn‟s disease include anti-
inflammatory drugs such as 5-aminosalicylic acid (5-ASA) 
and immunomodulators such as azathioprine, 
mercaptopurine, methotrexate, infliximab, adalimumab, 
certolizumab and natalizumab5, 6. Although these 
pharmaceutical compounds have shown to be effective 
against Crohn‟s disease, they show limited clinical 
efficiency and several side effects. The anti- inflammatory 
drug thalidomide has shown to be very successful in 
inhibiting the inflammation associated with Crohn‟s 
disease but presents side effects due to his high dose 
requirements 7.  Appropriate delivery systems must be 
developed in order to overcome the limitations and issues 
of the currently available treatment for Crohn‟s disease. 
Artificial cell microencapsulation is a promising tool in 
scientific research that allows for the delivery of 
pharmaceutical compounds to specific tissues in the body, 
in a time dependent fashion 8, 9. Creating an artificial cell 
involves the preparation of artificial structure of cellular 
dimension using different types of polymers and proteins. 
Although several encapsulation techniques are being used, 
the most promising formulation is the encapsulation of 
calcium alginate beads with poly-L-lysine (PLL), forming 
alginate-poly-L-lysine-alginate (APA) microcapsules 10. 
APA microcapsules are formed by the ionic interaction 
between negatively charged alginate molecules and 
positively charged calcium ions. This allows the entrapped 
material to be protected from the external environment. 
This paper proposes the use of APA microcapsules for the 
specific delivery of thalidomide to treat Crohn‟s disease. 
The goal of this study is to evaluate the drug release 
characteristics in different intestinal segments and to 
determine the effect of thalidomide on a simulated 
intestinal inflammation by using RAW 264.7 macrophage 
cells. 
 
MATERIAL AND METHODS 
Chemicals and laboratory equipment 
The Research IER-20 cell encapsulator was supplied by 
InotechBiosystems International. The Lab-Line Environ 
Shaker 3527 was supplied by Lab-Line Designers and 
Manufacturers and the Varian Cary 100 Bio 
Spectrophotometer was supplied by Varian. The chemicals 
thalidomide, alginic acid, poly –L-lysine (Hydrobromide) 
and dimethyl sulfoxide were supplied by Sigma-Aldrich 
Canada. 
 
Preparation of APA microcapsules containing 
thalidomide 
Figure 1 illustrates the preparation of APA microcapsules 
containing Thalidomide. Alginic acid was added to 
deionized water to make a 1.5% alginate solution. (±)- 
Thalidomide ((±)-2-(2,6-Dioxo-3-piperidinyl)-1H-
isoindole-1,3(2H)-dione) was dissolved in deionized water 
at a concentration of 0.035 mg/ml by stirring and heating 
for 24 hours and added to the alginate solution. Alginic 
acid was additionally added to maintain a 1.5% 
concentration after the thalidomide and water solution 
were included. APA beads were then formed by running 
the above solution through an Inotechencapsulator pump 
using a 300μm nozzle. Frequency was set to 528 Hz, flow 
rate to 20.8 ml/min and voltage to 1.48 kV. Formed beads 
were collected in a prepared 0.1M calcium chloride 
solution to avoid cell aggregation. The beads were then 
washed with deionized water and soaked in a 0.1% poly-l-
lysine bath for 10 minutes. Beads were washed again and 
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soaked in 0.15% alginate solution for 15 minutes. Final 
washing was done with water and beads were transferred 
into calcium chloride for storage. The capsules were 
visually evaluated for uniformity and integrity through a 
Lomo light microscope with 250X magnification.
 
 
Figure 1: Schematic diagram of the preparation of thalidomide loaded APA microcapsules 
 
Characterization of thalidomide 
A standard curve for thalidomide in deionized water was 
prepared. Thalidomide was dissolved in deionized water at 
a concentration of 0.035 mg/ml by stirring and heating for 
24 hours. The absorbance of different dilution factors was 
measured at 220 nm and plotted against the concentration 
of thalidomide in mM (Figure 2). 
 
Physical integrity of APA microcapsules 
In-vitro experiments were conducted to study the physical 
integrity of APA microcapsules containing thalidomide. In 
order to simulate in vivo shear stress, microcapsules were 
incubated for 48 h in saline solution and shaken at 150 rpm 
11. The percentage of damaged and undamaged 
microcapsules were visually determined using a light 
microscope from supernatant samples taken at 1h, 9h, 12h, 
24h and 48h after incubation. Pictures were taken before 
and after incubation to analyze the morphology of the 
microcapsule. Moreover, the release of thalidomide was 
measured spectrophotometrically over time as a marker of 
membrane permeability (Figure 4). 
 
Evaluating thalidomide release in simulated gastric and 
intestine fluid 
Simulated gastric fluid (SGF) and simulated intestine fluid 
(SIF) were prepared in order to mimic the external 
environment encountered in the stomach and small 
intestine. SGF was prepared by dissolving Sodium 
Chloride (NaCl) and pepsin in deionized water. 
Hydrochloric acid was added to acidify the solution. The 
final pH of the solution was 1.5. Then, 250 mg of dried 
APA microcapsules containing thalidomide was added to 1 
ml of SGF and shaken at 125 rpm for 30 min. The optical 
density at 220 nm (OD 220) was measured from the 
supernatant every 10 min and the results are shown in 
figure 5. SIF was prepared by dissolving potassium 
phosphate monobasic, sodium Hydroxide and pancreatin in 
deionized water. The pH of the solution was 6.5. In this 
experiment, 305 mg of APA microcapsules containing 
thalidomide were added to 1 ml of SIF and shaken at 125 
rpm from 60 min. The absorbance was measured from the 
supernatant every 10 min and plotted on Figure 6. 
 
Evaluating thalidomide release in full simulated 
gastrointestinal model 
In order to evaluate the survival and stability of APA 
microcapsules containing thalidomide in the 
gastrointestinal environment, different solutions were 
prepared. Such solutions were designed in order to mimic 
the stomach, the small intestine, the colon ascendans, the 
colon transversum and the colon descendans with respect 
to their pH. Table 1 describes the retention time and pH of 
each solution. 15.65 g of dry capsules was initially added 
to the first solution and shaken at 250 rpm for 46h. The 
desired pH was maintained by the continuous addition of 
HCl (0.102 M) and NaOH (0.2 M). OD 220 of supernatant 
was measured at several time points and the concentration 
of thalidomide was calculated in g/ml as shown in figure 7.  
 
Table 1: Retention time and pH of gastrointestinal 
solutions. Solutions 1 represent the stomach and small 
intestine respectively, while vessels 3, 4 and 5 represent 
the ascending colon, the transverse colon and the 
descending colon respectively. Fixed amount of APA 
microcapsules were added into these gastrointestinal 
solution and the concentration of thalidomide released was 
measured over 46 hrs incubation. 
 
Statistical analysis 
Values are expressed as mean ± SD. Study was considered 
a randomized balanced design. Statistical comparisons 
between various biomarkers were carried out by repeated 
measures analysis of variance (ANOVA). Statistical 
comparisons between various treatment groups were 
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carried out by using the general linear model (GLM). Statistical significance was set at p < 0.05. 
 
RESULTS AND DISCUSSION: 
Thalidomide standard curve 
The optical density at 220 nm was measured from the 
supernatant and plotted in Figure 2. Data suggest a direct 
proportionality between the optical density and 
thalidomide concentration. The mathematical equation 
y=45.464x, where y represents the absorbance at 220nm 
and x the concentration in mM, will be used for calculating 
the amount thalidomide in samples. 
 
 
Figure 2: Standard curve for calculating thalidomide concentration. All data are done in triplicate and the equation 
displayed on the chart was used for calculating the concentration of thalidomide in supernatant samples. 
 
Physical integrity of APA microcapsules 
In order to mimic in vivo shear stress, the APA 
microcapsules were incubated in saline solution for 48h 
and shaken at 150 rpm. The percentage of intact APA 
microcapsule was 96% ± 1 after incubation in saline for 
48h. APA microcapsules displayed a consistent spherical 
shape with a diameter of 350–400 μm (Figure 3). The 
majority of APA membrane is found intact after 48h hours 
of incubation in saline solution. The intact ratio of APA 
microcapsules is illustrated in table 2. Although the 
capsules were shaken at 150 rpm for 48h in saline solution, 
thalidomide was largely maintained inside the APA 
microcapsules. Data illustrated in Figure 4 suggests a 
minimal release of thalidomide after 48h (10.26 mM ± 
1.27 x10^-6 mM). 
 
Table 2: Percentage of intact APA microcapsules after incubation in saline for 48h and vigorous shaking at 150 rpm. 




Figure 3: Photomicrographs of APA microcapsules 
containing thalidomide before (left) and after (right) 
incubation in saline solution at 150 rpm under 250X 
magnification. Size ranges from 300-350 μm. 
  Figure 4: Thalidomide retention efficacy profile of APA 
microcapsules in saline. After 48h of incubation, the 
concentration of thalidomide measured from the 
supernatant was 12.29x10^-6mM. 
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Despite the large size of formed beads, this study showed 
that thalidomide was mainly maintained within the 
microcapsules after 48h of incubation in saline solution at 
150 rpm.This was largely due to the presence of 
electrostatic forces between the positively charged drug 
and the negatively charged alginate molecule. 
 
Evaluating thalidomide release in simulated gastric and 
intestine fluid 
The release of thalidomide was kept relatively constant 
following incubation of APA microcapsules in simulated 
gastric solution for 30 min. (Figure 5). Results show that 
after 30 min of incubation and shaking in simulated gastric 
fluid, thalidomide release was minimal (9.43%). However, 
after incubation in simulated intestine fluid, the percentage 
release of thalidomide significantly increased (Figure 6). 
After 10 min incubation in SIF, the percentage release of 
thalidomide was 72.89%, and reached a value of 82.79% 
following 30 min incubation. Maximal release of 
thalidomide was achieved after 60 min incubation in 
SIF.These results demonstrated the fact that APA 
microcapsules are specifically designed to protect the 
entrapped material from the harsh acidic conditions 
normally found in the stomach, while allowing the 
encapsulated material to be slowly released in the 
intestines. 
Evaluating thalidomide release in full simulated 
gastrointestinal model 
Figure 7 illustrates the release profile of thalidomide in 
solutions simulating the acidic and basic conditions 
normally encountered in the stomach, the small intestine, 
the colon ascendans, the colon transversum and the colon 
descendans. Data suggest that thalidomide release from 
APA microcapsules is pH-dependent. Thalidomide release 
is minimal at pH 2.32 (6.25x10^-7 g/ml) but dramatically 
increases when the pH is above 5.31 to finally reach a peak 





Figure 5: Thalidomide release from APA microcapsules in 
simulated gastric fluid. The percentage release of 
thalidomide is 9.38 ± 0.04 %, 9.39 ± 0.39% and 9.43 ± 
0.04 % at time 10, 20 and 30 min respectively. Values are 




Figure 6: Thalidomide delivery profile of APA 
microcapsules in simulated intestine fluid. The average 
percentage release of thalidomide is 99.72 ± 0.06 % after 
60 min of incubation. Values are expressed as mean + S.D. 




Figure 7: Thalidomide delivery by APA microcapsules in simulated gastrointestinal fluids. Results suggest a burst release 
of thalidomide when the APA microcapsules are transferred from low pH (2.32) to a high pH (5.31) environment. Maximal 
drug release is observed when the microcapsules are transferred in a pH=6.2 and pH=6.74 environments. 
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This figure shows that an increase in pH triggers the 
release of thalidomide from APA microcapsules. This can 
be explained by the fact that the membrane of APA 
microcapsule is composed of two layers of alginate and 




This experiment was aimed at determining the mechanical 
strength of APA microcapsules in vitro and analyse the 
drug release profile with respect to change in pH and 
external environment. APA microcapsule containing 
thalidomide has shown to be stable and the membrane 
retained its original shape and integrity. This characteristic 
of APA microcapsules makes it an appropriate carrier for 
drug delivery by oral administration. Moreover, the present 
study showed that the release of thalidomide from APA 
microcapsules is significantly increased when the capsules 
are transferred from a simulated gastric fluid into a 
simulated intestine fluid, demonstrating the ability of the 
microcapsules to prevent the delivery of thalidomide in the 
stomach while allowing its slow release in the intestines. 
Moreover, results demonstrated a burst release of 
thalidomide,which strongly suggests that the pH of the 
external solution plays a crucial role on the mechanical 
strength and stability of the APA membrane. This 
important characteristic of APA microcapsule could be 
useful in the treatment of Crohn's disease where local 
delivery of the encapsulated drug to affected sites of the 
gastrointestinal tract is required.However, further in-vivo 
studies are needed to evaluate the full capacity of 
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